Researchers have identified a second path to defeating chronic myelogenous leukemia, which tends to affect older adults, even in the face of resistance to existing drugs.
Sep 21, 2020
0
28
Today, ASH published new guidelines to help older adults with acute myeloid leukemia (AML) and their health care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for ...
Aug 06, 2020
0
2
(HealthDay)—For children and young adults receiving CD19 chimeric antigen receptor (CAR) T-cell infusion (CTI), infection rates increase in the first month after treatment and then decrease, according to a study published ...
May 29, 2020
0
2
Scientists at St. Jude Children's Research Hospital and Princess Margaret Cancer Centre in Toronto, Canada, have reported that subpopulations of leukemic cells present at diagnosis can cause relapse in children with acute ...
Mar 03, 2020
0
9
Patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heightened risk of heart failure—most often within one year of exposure to the chemotherapy treatment, ...
Dec 17, 2019
0
3
New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic ...
Dec 10, 2019
0
1
A new study in JNCI Cancer Spectrum finds that exposure to radiation from CT scans is associated with higher risks of developing thyroid cancer and leukemia.
Nov 19, 2019
1
4
Henry Ford Cancer Institute has treated its first patient with CAR T-cell therapy, an approach that uses engineered cells from a patient's immune system to destroy cancer. The altered cells remain active for years after the ...
Jun 18, 2019
0
3
(HealthDay)—Venetoclax (VENCLEXTA) has been approved to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, the U.S. Food and Drug Administration announced yesterday.
May 17, 2019
0
1
Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation compared with standard chemotherapy regimens, ...
Apr 01, 2019
0
3
